A Study to Explore Clinical Characteristics and Prognoses of N2 Patients With Non-small Cell Lung Cancer

A Multi-centre Real-world Non-interventional Observational Study to Explore Clinical Characteristics of Lymph Skip Metastases and Prognoses of N2 Patients With Non-small Cell Lung Cancer

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03429192

Enrollment

2653

Registered

2018-02-12

Start date

2017-12-01

Completion date

2018-03-30

Last updated

2018-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small Cell Lung Cancer

Keywords

Chinese, real-world evidences, NSCLC, lymph skip metastases

Brief summary

A study to compare patient survivals in the N2 patients with non-small cell lung cancer in the subgroups of lymph skip metastases and non-skip metastases

Detailed description

A multi-centre real-world non-interventional observational study to retrospectively collect the study data on patient demographic/tumor biological characteristics and clinical treatments to compare patient survivals in the N2 patients with non-small cell lung cancer in the subgroups of lymph skip metastases and non-skip metastases.

Interventions

PROCEDURESurgery

Surgeries plus dissection of lymph nodes

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients with surgeries from 2014 to 2017; * Pathologically diagnosed patients with non-small cell lung cancer; * Age \> 18 years old; * Patients with chest surgeries before hospitalization; * Patients with N2 lymph nodes (+) after surgeries who received lymphadenectomy (Group 10 and 11 lymph nodes);

Exclusion criteria

\- Patients with radiotherapies, chemotherapies and biological therapies for tumors

Design outcomes

Primary

Measure	Time frame	Description
Difference in overall survival (OS)	2014 - 2017	OS difference in the subgroups of N2 patients with lymph skip metastases and non-skip metastases

Secondary

Measure	Time frame	Description
Percentage of N2 patients with lymph skip metastases	2014 - 2017	Percentage of N2 patients with lymph skip metastases

Other

Measure	Time frame	Description
Difference in overall survival (OS) (in the subgroups of patients)	2014 - 2017	OS difference in subgroups of patients with lymph skip metastases and non-skip metastases categorised by baseline characteristics
Hazard factors of overall survival	2014 - 2017	Hazard factors of overall survival

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 1, 2026